Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

S1200000

Spironolactone

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C24H32O4S
Numero CAS:
52-01-7
Peso molecolare:
416.57
Numero MDL:
MFCD00082250
Codice UNSPSC:
41116107
ID PubChem:
329824467
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

spironolactone

Produttore/marchio commerciale

EDQM

Punto di fusione

207-208 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
LXMSZDCAJNLERA-ZHYRCANASA-N

Informazioni sul gene

human ... NR3C2(4306)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Spironolactone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H351,H360FD,H373

Classi di pericolo

Carc. 2 - Repr. 1B - STOT RE 2

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

Eplerenone ≥98% (HPLC)

Sigma-Aldrich

E6657

Eplerenone

Prednisone British Pharmacopoeia (BP) Reference Standard

BP553

Prednisone

Midostaurin hydrate ≥98% (HPLC), solid

Sigma-Aldrich

M1323

Midostaurin hydrate

Aldosterone-2,2,4,6,6,21,21-d7 ≥98 atom % D (based on d7), ≥98% (CP)

Sigma-Aldrich

706035

Aldosterone-2,2,4,6,6,21,21-d7

Benazepril hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B0935

Benazepril hydrochloride

Enalaprilat United States Pharmacopeia (USP) Reference Standard

USP

1235274

Enalaprilat

Aldosterone ≥95% (HPLC)

Sigma-Aldrich

A9477

Aldosterone

Mifepristone ≥98%

Sigma-Aldrich

M8046

Mifepristone

Everolimus ≥95% (HPLC)

Sigma-Aldrich

SML2282

Everolimus

Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Christopher J A Neil et al.
JAMA, 310(2), 204-204 (2013-07-11)
D A Andreev et al.
Kardiologiia, 53(3), 94-96 (2013-04-04)
It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors. The patient (75 years old) at the decompensation of chronic heart failure in
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Lars H Lund et al.
JAMA, 310(2), 205-205 (2013-07-11)
Adam D Karns et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(3), 186-192 (2013-03-06)
Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension. Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland. In this study, the efficacy
Prescrire international, 22(139), 148-149 (2013-07-20)
Still no randomised controlled trials versus spironolactone, but a prematurely terminated placebo-controlled trial with 2737 patients.
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.